

Emerald Health Therapeutics Inc. completes C\$13.8M bought deal financing

Date closed: 2/10/2017

Value: C\$13.5 million

On February 10, 2017, Emerald Health Therapeutics Inc. (Emerald Health or the Company) closed its bought deal public offering of 10,235,000 units at a price of \$1.35 per unit for aggregate gross proceeds of \$13,817,250, which included the exercise in full of the underwriters' over-allotment option. Each unit consists of one common share of the Company and one-half of one common share purchase warrant. The offering was underwritten by Eight Capital (formerly Dundee Capital Partners).

Emerald Health, headquartered in Victoria, British Columbia, is engaged in the business of producing and selling medical marijuana.

BLG represented Eight Capital with a team led by Andrew Powers that included <u>Philippe Tardif</u>, Linda Tu, Joseph DiPonio and Danny Lang.

For more information, please contact:

Tamara Costa

National Director, Marketing and Communications Borden Ladner Gervais LLP <u>TCosta@blg.com</u> 416.350.2642



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.